IPRATROPIUM BROMIDE

Post-LOE

ipratropium bromide

Rubicon Biotechnology

ANDANASALSPRAY, METERED

Approved

Feb 2025

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

IPRATROPIUM BROMIDE (ipratropium bromide) by Rubicon Biotechnology is clinical pharmacology mechanism of action ipratropium bromide is an anticholinergic (para sympatholytic) agent which, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in the lung. Approved for chronic obstructive pulmonary disease. First approved in 2025.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Mechanism of Action Ipratropium bromide is an anticholinergic (para sympatholytic) agent which, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in…

Worked on IPRATROPIUM BROMIDE at Rubicon Biotechnology? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (8)

NCT01943552Phase 4Completed

Ipratropium Bromide in Peri-Operative COPD

Started Oct 2013

192 enrolled

Pulmonary Disease, Chronic Obstructive

NCT00911651Phase 4Completed

Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients

Started Jun 2008

6 enrolled

COPD

NCT02177253Phase 3Completed

Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease

Started Oct 2002

1,118 enrolled

Pulmonary Disease, Chronic Obstructive

NCT02236169Phase 2Completed

Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Started Oct 2000

30 enrolled

Pulmonary Disease, Chronic Obstructive

NCT02260011Phase 2Completed

Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease

Started Oct 2000

41 enrolled

Pulmonary Disease, Chronic Obstructive

IPRATROPIUM BROMIDE

Mechanism of Action

Indications (1)

Clinical Trials (8)